Focus: NeoLight develops phototherapy devices, specifically phototherapy mattresses and beds, for treating neonatal jaundice (hyperbilirubinemia). The company operates as a specialized medical device/biotech firm focused on a narrow but clinically important neonatal care segment.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow NeoLight to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Primary product candidate for treating elevated bilirubin in newborns; currently in early-stage clinical evaluation.
Help build intelligence for NeoLight
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from NeoLight's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Secondary phototherapy bed platform targeting the same neonatal jaundice market as the mattress product.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo